Literature DB >> 1768156

Inhibitory effects of anticardiolipin antibodies on lymphocyte proliferation and neutrophil phagocytosis.

C L Yu1, K H Sun, C Y Tsai, S R Wang.   

Abstract

Anticardiolipin antibodies purified from serum from patients with systemic lupus erythematosus (SLE) by cardiolipin micelles were studied for their effects on lymphocytes and neutrophils. At a concentration of 160 micrograms/ml they markedly suppressed the [3H]thymidine incorporation of mononuclear cells stimulated by phytohaemagglutinin (4.9 (SEM 1.9%) of the control) and pokeweed mitogen (26.7 (10.5%) of the control). In addition, anticardiolipin antibodies changed the cell cycle of phytohaemagglutinin stimulated lymphocytes such that the S and G2+M phases were significantly diminished (G0/G1 = 64.62%, S = 20.59%, G2+M = 14.78% in the presence of normal human IgG v G0/G1 = 86.07%, S = 10.32%, G2+M = 3.59% in the presence of anticardiolipin antibodies). The suppression of lymphocyte proliferation by anticardiolipin antibodies was shown not to be caused by an alteration of T cell subpopulations. However, the interleukin 2 receptors on the cell surface and the soluble interleukin 2 receptors in the supernatant of phytohaemagglutinin stimulated mononuclear cells were decreased in the presence of anticardiolipin antibodies. On the other hand, the phagocytic activity of neutrophils was 40% inhibited at a higher concentration of anticardiolipin antibodies (300 micrograms/ml) through suppression of C3b/C4b and Fc receptors on polymorphonuclear leucocytes. These results suggest that anticardiolipin antibodies exert inhibitory effects on both lymphocytes and phagocytes in addition to the coagulation cascade. These newly found activities of anticardiolipin antibodies were mediated by the non-specific membranotropic property of the antibodies.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1768156      PMCID: PMC1004578          DOI: 10.1136/ard.50.12.903

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  36 in total

1.  THROMBOSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS DESPITE CIRCULATING ANTICOAGULANTS.

Authors:  E J BOWIE; J H THOMPSON; C A PASCUZZI; C A OWEN
Journal:  J Lab Clin Med       Date:  1963-09

2.  The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies.

Authors:  R A Fields; H Toubbeh; R P Searles; A D Bankhurst
Journal:  J Rheumatol       Date:  1989-05       Impact factor: 4.666

3.  Vasculopathy in the antiphospholipid syndrome: thrombosis or vasculitis, or both?

Authors:  J T Lie
Journal:  J Rheumatol       Date:  1989-06       Impact factor: 4.666

4.  Antiphospholipid arterial vasculopathy.

Authors:  D Alarcón-Segovia; M H Cardiel; E Reyes
Journal:  J Rheumatol       Date:  1989-06       Impact factor: 4.666

5.  Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes.

Authors:  M A Khamashta; E N Harris; A E Gharavi; G Derue; A Gil; J J Vázquez; G R Hughes
Journal:  Ann Rheum Dis       Date:  1988-10       Impact factor: 19.103

6.  Defective phagocytosis, decreased tumour necrosis factor-alpha production, and lymphocyte hyporesponsiveness predispose patients with systemic lupus erythematosus to infections.

Authors:  C L Yu; K L Chang; C C Chiu; B N Chiang; S H Han; S R Wang
Journal:  Scand J Rheumatol       Date:  1989       Impact factor: 3.641

7.  Endothelial prostacyclin release in systemic lupus erythematosus.

Authors:  S B Coade; E van Haaren; S Loizou; M J Walport; A M Denman; J D Pearson
Journal:  Thromb Haemost       Date:  1989-02-28       Impact factor: 5.249

8.  Antiphospholipid antibodies in the connective tissue diseases: their relation to the antiphospholipid syndrome and forme fruste disease.

Authors:  R R Buchanan; J R Wardlaw; A G Riglar; G O Littlejohn; M H Miller
Journal:  J Rheumatol       Date:  1989-06       Impact factor: 4.666

9.  Hemocytopenia in systemic lupus erythematosus. Relationship to antiphospholipid antibodies.

Authors:  M Delezé; D Alarcón-Segovia; C V Oria; J Sánchez-Guerrero; L Fernández-Dominguez; L Gomez-Pacheco; S Ponce de León
Journal:  J Rheumatol       Date:  1989-07       Impact factor: 4.666

10.  Interleukin 1 and tumor necrosis factor stimulate human vascular endothelial cells to promote transendothelial neutrophil passage.

Authors:  R Moser; B Schleiffenbaum; P Groscurth; J Fehr
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

View more
  4 in total

1.  Effect of antibodies to double stranded DNA, purified from serum samples of patients with active systemic lupus erythematosus, on the glomerular mesangial cells.

Authors:  C Y Tsai; T H Wu; K H Sun; C L Yu
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

2.  Inhibition of astrocyte proliferation and binding to brain tissue of anticardiolipin antibodies purified from lupus serum.

Authors:  K H Sun; W T Liu; C Y Tsai; T S Liao; W M Lin; C L Yu
Journal:  Ann Rheum Dis       Date:  1992-06       Impact factor: 19.103

3.  A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs.

Authors:  Michael F Denny; Srilakshmi Yalavarthi; Wenpu Zhao; Seth G Thacker; Marc Anderson; Ashley R Sandy; W Joseph McCune; Mariana J Kaplan
Journal:  J Immunol       Date:  2010-02-17       Impact factor: 5.422

4.  Presence of Anticardiolipin Antibodies in Patients with Dementia: A Systematic Review and Meta-Analysis.

Authors:  Md Asiful Islam; Fahmida Alam; Mohammad Amjad Kamal; Siew Hua Gan; Teguh Haryo Sasongko; Kah Keng Wong
Journal:  Front Aging Neurosci       Date:  2017-08-02       Impact factor: 5.750

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.